Mark Messier

Mark Messier is the founder of BioRunUp.com. Messier is a Department of Justice-certified Criminal Intelligence Analyst and former IT professional, specializing in law-enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profits in four years. In April 2010, Messier founded the subscription-based stock-trading Web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

Recent Articles By The Author

The Run-Up Trade: Biodel's Insulin Trial Results

The Run-Up Trade: Biodel's Insulin Trial Results

Biodel shares should move higher ahead of insulin trial results in the third quarter.

Rockwell Medical Run-Up Trade Follows Financing

Rockwell Medical Run-Up Trade Follows Financing

One trader believes Rockwell shares will rise into clinical trial results expected in July.

Synta Is Run-Up to ASCO Lung Cancer Data

Synta Is Run-Up to ASCO Lung Cancer Data

The market overreacted to the resignation of Synta's R&D chief.

Expecting Ziopharm Shares To Run Into Phase III Data At Month's End

Expecting Ziopharm Shares To Run Into Phase III Data At Month's End

Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.

Run-Up Trade Into Dynavax's FDA Approval Decision

Run-Up Trade Into Dynavax's FDA Approval Decision

Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.